共 255 条
[1]
Fruman DA(2017)The PI3K pathway in human disease Cell 170 605-635
[2]
Chiu H(2004)High frequency of mutations of the PIK3CA gene in human cancers Science 304 554-713
[3]
Hopkins BD(2017)Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Nat Med 23 703-832 e823
[4]
Bagrodia S(2017)A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR pathway alterations Cancer Cell 31 820-775
[5]
Cantley LC(2004)The PIK3CA gene is mutated with high frequency in human breast cancers Cancer Biol Ther 3 772-438 e426
[6]
Abraham RT(2018)The genomic landscape of endocrine-resistant advanced breast cancers Cancer Cell 34 427-11000
[7]
Samuels Y(2005)Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells Cancer Res 65 10992-807
[8]
Wang Z(2005)Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic Proc Natl Acad Sci U S A 102 802-916
[9]
Bardelli A(2017)Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 18 904-100
[10]
Silliman N(2018)Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 19 87-1668